The ARHGEF40 knockout HT29 polyclonal cell product is a CRISPR/Cas9-edited polyclonal population derived from the HT29 human colorectal adenocarcinoma cell line, engineered to disrupt the ARHGEF40 gene. This gene disruption results in a loss-of-function model that eliminates the expression of ARHGEF40, a guanine nucleotide exchange factor (GEF) specific for the small GTPase RhoA. The polyclonal format represents a heterogeneous pool of edited cells, providing a robust system for studying the collective consequences of ARHGEF40 ablation without the selective pressures of clonal isolation. This population-based knockout approach facilitates the examination of ARHGEF40-dependent phenotypes in a context that mitigates potential clone-specific artifacts inherent to monoclonal lines.
The HT29 cell line, derived from a colorectal tumor of a 44-year-old Caucasian female, is a widely used model of colonic epithelial cells and colorectal adenocarcinoma. HT29 cells exhibit intestinal epithelial differentiation features under proper conditions, including polarized monolayer formation and brush-border enzyme expression. Their tumorigenic and epithelial nature makes them relevant for colorectal cancer research. Introducing an ARHGEF40 knockout into this background allows direct assessment of the gene??s role in migration, invasion, and adhesion in a disease-relevant setting.
ARHGEF40 functions as a critical activator of RhoA, catalyzing GDP-to-GTP exchange. Phosphorylated by upstream kinases SYK and SRC, it links integrin and Wnt ligand stimulation to RhoA activation. GTP-loaded RhoA activates ROCK, which phosphorylates MLC and drives actin stress fiber assembly, modulating contractility and motility. ARHGEF40 interacts with ??-catenin (CTNNB1) and AJUBA, integrating RhoA and Wnt/??-catenin signaling. This positions ARHGEF40 at a nexus of cytoskeletal dynamics and transcriptional regulation, affecting focal adhesion turnover and cell migration.
In colorectal cancer, dysregulation of RhoA signaling contributes to tumor invasion and metastasis. The ARHGEF40 knockout HT29 model provides a defined platform to dissect how loss of this GEF alters RhoA activity and downstream actin remodeling in a colonic epithelial background. Given the crosstalk between ARHGEF40 and ??-catenin, this model also enables exploration of how ARHGEF40 deficiency impacts Wnt pathway activity and cellular responses to external cues like integrin engagement. By eliminating ARHGEF40 function, researchers can unravel its specific roles in maintaining the transformed phenotype of HT29 cells, potentially revealing vulnerabilities that could be targeted for therapeutic intervention.
Researchers may employ this polyclonal knockout product for a diverse range of applications, including quantitative assays of RhoA-GTP levels via pull-down methods, immunofluorescence visualization of actin stress fiber organization, and functional studies using scratch wound healing and Transwell invasion to evaluate cell migration and invasion. The model is also suitable for drug sensitivity and resistance profiling to assess how ARHGEF40 loss affects therapeutic responses, and for apoptotic and viability assays to monitor survival signaling. Western blotting can confirm knockout efficiency and monitor pathway components such as ROCK, MLC, and ??-catenin. For additional details and technical assistance, please contact Ascent Research.
